choline has been researched along with Recrudescence in 77 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke." | 8.02 | Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021) |
| "We report the incidental finding of a pituitary macroadenoma on an F-choline PET/CT in a patient with recurrent prostate cancer." | 7.83 | Pituitary Non-Functioning Adenoma Disclosed at 18F-Choline PET/CT to Investigate a Prostate Cancer Relapse. ( Colletti, PM; Maffione, AM; Mandoliti, G; Pasini, F; Rubello, D, 2016) |
| "For a biochemical recurrence of disease (prostate-specific antigen level, 0." | 5.51 | Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. ( Di Gregorio, F; Evangelista, L; Ferretti, G; Rensi, M, 2019) |
| "F-FDG PET showed no uptake of the residual tumor, whereas F-choline depicted highly metabolic residual disease uptake with excellent delineation of local recurrence." | 5.51 | 18F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence. ( Cassou-Mounat, T; Huchet, V; Jehanno, N; Luporsi, M; Mammar, H, 2019) |
| "We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke." | 4.02 | Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021) |
| "To compare the performance of the quantitative analysis of the hepatobiliary phase (HBP) tumor enhancement in gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI and of dual-tracer 18F-FDG and 18F-fluorocholine (FCH) PET/CT for the prediction of tumor aggressiveness and recurrence-free survival (RFS) in resectable hepatocellular carcinoma (HCC)." | 3.96 | Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. ( Amaddeo, G; Calderaro, J; Chalaye, J; Galletto Pregliasco, A; Itti, E; Kharrat, R; Kobeiter, H; Laurent, A; Legou, F; Luciani, A; Mulé, S; Regnault, H; Tacher, V; Tenenhaus, A, 2020) |
| "We report the incidental finding of a pituitary macroadenoma on an F-choline PET/CT in a patient with recurrent prostate cancer." | 3.83 | Pituitary Non-Functioning Adenoma Disclosed at 18F-Choline PET/CT to Investigate a Prostate Cancer Relapse. ( Colletti, PM; Maffione, AM; Mandoliti, G; Pasini, F; Rubello, D, 2016) |
| "The authors examined the levels of NAA, creatine plus phosphocreatine, and choline-containing molecules in the left dorsolateral prefrontal cortex of 14 bipolar disorder patients (mean age=15." | 3.73 | Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients. ( Axelson, D; Birmaher, B; Brambilla, P; Keshavan, MS; Nicoletti, MA; Ramos, RT; Ryan, N; Sassi, RB; Soares, JC; Stanley, JA, 2005) |
| "In the multiple sclerosis white matter lesions, N-acetylaspartate (NAA), choline (Cho), inositol (Ins), and creatine (Cr) peaks did not vary significantly over the entire period of the study in the untreated group." | 3.70 | 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. ( Alberti, A; Gallai, V; Gobbi, G; Orlacchio, A; Pelliccioli, GP; Presciutti, O; Sarchielli, P; Tarducci, R, 1998) |
| "Prostate cancer is the second leading cause of cancer-related deaths in men in the United States." | 3.01 | PSMA PET imaging in the diagnosis and management of prostate cancer. ( Behr, S; Houshmand, S; Lawhn-Heath, C, 2023) |
| "This prospective study included 250 prostate cancer patients with PSA relapse who underwent (18)F-FCH PET/CT." | 2.78 | Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. ( Beheshti, M; Haim, S; Kunit, T; Langsteger, W; Loidl, W; Nader, M; Steinmair, M; Waldenberger, P; Zakavi, R, 2013) |
| "Findings consistent with recurrent prostate cancer were noted on FCH PET/CT in 31/50 (62%) patients, with positive findings in 17/18 (94%), and 11/13 (85%), 2/7 (29%), and 1/12 (8%) patients with PSA >4, >2-4, >0." | 2.77 | Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging. ( Coel, MN; Kwee, SA; Lim, J, 2012) |
| "In patients with advanced head and neck cancer who have received combined therapy, a second post-treatment PET/CT examination to check for late recurrences should be performed within 4-6 months after the first post-treatment PET/CT examination." | 2.75 | 18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. ( Ito, K; Kubota, K; Matsuda, H; Morooka, M; Shiibashi, M; Yokoyama, J, 2010) |
| "Twenty patients had depression recurrence, and 23 patients reached AD discontinuation." | 1.62 | Choline elevation in amygdala region at recovery indicates longer survival without depressive episode: a magnetic resonance spectroscopy study. ( Bajs Janović, M; Erdeljić Turk, V; Foro, T; Henigsberg, N; Hrabač, P; Kalember, P; Ozretić, D; Radoš, M; Šarac, H; Savić, A; Šečić, A, 2021) |
| "Patients with prostate cancer are monitored by prostate-specific antigen (PSA) evaluation and PET [PET/computed tomography (CT)]." | 1.51 | 18F-choline positron emission tomography/computed tomography for the detection of prostate cancer relapse: assessment of maximum standardized uptake value correlation with prostate-specific antigen levels. ( Cholewiński, W; Czepczyński, R; Miechowicz, I; Ruchała, M; Siminiak, N; Wojciechowska, K, 2019) |
| "For a biochemical recurrence of disease (prostate-specific antigen level, 0." | 1.51 | Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. ( Di Gregorio, F; Evangelista, L; Ferretti, G; Rensi, M, 2019) |
| "F-FDG PET showed no uptake of the residual tumor, whereas F-choline depicted highly metabolic residual disease uptake with excellent delineation of local recurrence." | 1.51 | 18F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence. ( Cassou-Mounat, T; Huchet, V; Jehanno, N; Luporsi, M; Mammar, H, 2019) |
| "In patients with early recurrence of PC, F-FCH PET/CT is able to detect OMD in 40% of cases." | 1.48 | Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml. ( Agostini, A; Basso, U; Cuppari, L; Evangelista, L; Gardi, M; Guttilla, A; Ruggera, L; Saladini, G, 2018) |
| "Patients with suspected recurrence of prostate cancer undergoing [18F]fluoromethyl choline ([18F]FCH) PET/CT were retrospectively evaluated to investigate the influence of hormonal therapy (HT) in [18F]FCH uptake." | 1.43 | Influence of hormonal therapy in prostate cancer patients undergoing [18F]fluoromethyl choline PET/CT: a retrospective study. ( Aristei, C; Bellavita, R; Buresta, T; Ferretti, F; Fravolini, ML; Mearini, L; Palumbo, B; Palumbo, I; Pelliccia, G; Radicchia, V; Scialpi, M; Sivolella, S, 2016) |
| "multi-parametric MRI in the prostate cancer relapse." | 1.42 | (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer. ( Cozar, M; Escobar, M; Garcia, JR; Moragas, M; Romera, N; Soler, M, 2015) |
| "Early F-choline images improve pelvic prostate cancer lesion clarity." | 1.42 | Optimized protocol for (18)F-choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases. ( Chondrogiannis, S; Colletti, PM; Grassetto, G; Marzola, MC; Massaro, A; Rampin, L; Rubello, D, 2015) |
| "The reviewers assessed for local recurrence in the prostatectomy bed as well as LN and bone metastases, rating their diagnostic confidence with a 5-point scoring system for each location." | 1.40 | Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. ( Froemming, AT; Hagen, CE; Kawashima, A; Kitajima, K; Murphy, RC; Nathan, MA; Takahashi, N, 2014) |
| "In the present case, atypical cancer recurrence in the right distal lower leg was suspected on 18F-FEC PET/CT in a patient with a history of prostate cancer and an increased prostate-specific antigen level." | 1.40 | Unexpected diagnosis of peripheral schwannoma on 18F-fluoroethylcholine PET/CT for localization of prostate cancer recurrence and biopsy under real-time PET/ultrasound fusion guidance. ( Drescher, R; Freesmeyer, M; Winkens, T, 2014) |
| "Fifty-five patients with biopsy-proven prostate cancer or suspected recurrent prostate cancer were examined with simultaneous [18F] choline Positron emission tomography (PET)/MRI at 3 T." | 1.40 | Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis. ( Heusch, P; Lauenstein, TC; Lipponer, C; Nagarajah, J; Nensa, F; Pöppel, TD; Rübben, H; Schlosser, TW; Wetter, A, 2014) |
| "To evaluate, in prostate cancer (PCa) patients the potential of (11)C-choline PET/CT as a guide to helical tomotherapy (HTT) of lymph-node (LN) relapses with simultaneous integrated boost (SIB)." | 1.40 | (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. ( Berardi, G; Busnardo, E; Crivellaro, C; Di Muzio, N; Fiorino, C; Fodor, A; Gianolli, L; Giovacchini, G; Incerti, E; Kirienko, M; Messa, C; Picchio, M, 2014) |
| "Disease relapse was local in 17% of cases, distant in 66%, and combined in 17%." | 1.39 | Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. ( Al-Nahhas, A; Castellucci, P; Chondrogiannis, S; Colletti, PM; Ferretti, A; Grassetto, G; Marcolongo, A; Marzola, MC; Massaro, A; Picchio, M; Rampin, L; Rubello, D, 2013) |
| "The early detection of the site of recurrence could lead to a prompt instauration of the most appropriate treatment, i." | 1.37 | Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? ( Allegri, V; Ambrosini, V; Boschi, S; Castellucci, P; Fanti, S; Fuccio, C; Martorana, G; Marzola, MC; Montini, GC; Nanni, C; Rubello, D; Santi, I; Schiavina, R, 2011) |
| "Recurrences were eventually confirmed in eight patients after the posttreatment PET/CT examination." | 1.36 | Comparison of 18F-FDG and 11C-choline PET/CT for detecting recurrences in patients with nonsquamous cell head and neck malignancies. ( Ito, K; Kubota, K; Morooka, M; Yokoyama, J, 2010) |
| "The neural underpinnings of major depressive disorder (MDD) are unknown but there is evidence for structural alteration in the hippocampus that may become more pronounced over the course of illness." | 1.35 | Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study. ( Hall, GB; MacQueen, GM; Milne, A; Soreni, N; Yucel, K, 2009) |
| "One hundred consecutive prostate cancer patients with a persistent increase in serum PSA (>0." | 1.33 | [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. ( Baresic, T; Borsatti, E; Bortolus, R; Canzonieri, V; Cimitan, M; Drigo, A; Garbeglio, A; Morassut, S; Trovò, MG, 2006) |
| "In pretreated glioblastoma metabolic data of MRSI seem to be potentially helpful to differentiate tumorous and non tumorous enhancement phenomena after local immunotherapy, which might be useful for further treatment decisions." | 1.31 | Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastoma--Report of two exceptional cases. ( Engelbrecht, V; Floeth, FW; Weber, F; Wittsack, HJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.30) | 18.7374 |
| 1990's | 5 (6.49) | 18.2507 |
| 2000's | 9 (11.69) | 29.6817 |
| 2010's | 54 (70.13) | 24.3611 |
| 2020's | 8 (10.39) | 2.80 |
| Authors | Studies |
|---|---|
| Langé, M | 1 |
| Magné, N | 1 |
| Zhou, K | 1 |
| Bellanger, M | 1 |
| Latorzeff, I | 1 |
| Pommier, P | 1 |
| Martin, E | 2 |
| Paumier, A | 1 |
| Béra, G | 1 |
| Supiot, S | 1 |
| Houshmand, S | 1 |
| Lawhn-Heath, C | 1 |
| Behr, S | 1 |
| Henigsberg, N | 2 |
| Savić, A | 2 |
| Radoš, M | 4 |
| Šarac, H | 2 |
| Šečić, A | 2 |
| Bajs Janović, M | 2 |
| Foro, T | 1 |
| Ozretić, D | 2 |
| Erdeljić Turk, V | 2 |
| Hrabač, P | 2 |
| Kalember, P | 2 |
| Siminiak, N | 1 |
| Wojciechowska, K | 1 |
| Miechowicz, I | 1 |
| Cholewiński, W | 1 |
| Ruchała, M | 1 |
| Czepczyński, R | 1 |
| Witkowska-Patena, E | 1 |
| Giżewska, A | 1 |
| Dziuk, M | 1 |
| Miśko, J | 1 |
| Budzyńska, A | 1 |
| Walęcka-Mazur, A | 1 |
| Nguyen, BD | 1 |
| Heller, MT | 1 |
| Roarke, MC | 1 |
| Mulé, S | 1 |
| Chalaye, J | 1 |
| Legou, F | 1 |
| Tenenhaus, A | 1 |
| Calderaro, J | 1 |
| Galletto Pregliasco, A | 1 |
| Laurent, A | 1 |
| Kharrat, R | 1 |
| Amaddeo, G | 1 |
| Regnault, H | 1 |
| Tacher, V | 1 |
| Kobeiter, H | 1 |
| Itti, E | 1 |
| Luciani, A | 1 |
| Evangelista, L | 5 |
| Ravelli, I | 1 |
| Magnani, F | 1 |
| Iacobone, M | 1 |
| Giraudo, C | 1 |
| Camozzi, V | 1 |
| Spimpolo, A | 1 |
| Cecchin, D | 1 |
| Telo, S | 1 |
| Fanti, S | 8 |
| Nanni, C | 4 |
| Lambertini, A | 1 |
| Picchio, M | 4 |
| Gianolli, L | 2 |
| Schiavina, R | 6 |
| Bianchi, L | 1 |
| Briganti, A | 1 |
| Mapelli, P | 1 |
| Castellucci, P | 9 |
| Farolfi, A | 1 |
| Zhong, C | 1 |
| Miao, M | 1 |
| Che, B | 1 |
| Du, J | 1 |
| Wang, A | 1 |
| Peng, H | 1 |
| Bu, X | 1 |
| Zhang, J | 1 |
| Ju, Z | 1 |
| Xu, T | 1 |
| He, J | 1 |
| Zhang, Y | 1 |
| Haroon, A | 1 |
| Syed, R | 1 |
| Endozo, R | 1 |
| Allie, R | 1 |
| Freeman, A | 1 |
| Emberton, M | 1 |
| Bomanji, J | 1 |
| Hatzl, M | 1 |
| Röper-Kelmayr, JC | 1 |
| Fellner, FA | 1 |
| Gabriel, M | 1 |
| Vadi, SK | 1 |
| Singh, B | 1 |
| Basher, RK | 1 |
| Watts, A | 1 |
| Sood, AK | 1 |
| Lal, A | 1 |
| Kakkar, N | 1 |
| Singh, SK | 1 |
| Parekh, A | 1 |
| Hagan, I | 1 |
| Capaldi, L | 1 |
| Lyburn, I | 1 |
| Cuppari, L | 1 |
| Guttilla, A | 3 |
| Gardi, M | 1 |
| Agostini, A | 1 |
| Ruggera, L | 1 |
| Basso, U | 1 |
| Saladini, G | 2 |
| Lépinoy, A | 1 |
| Silva, YE | 1 |
| Bertaut, A | 1 |
| Quivrin, M | 1 |
| Aubignac, L | 1 |
| Cochet, A | 1 |
| Créhange, G | 1 |
| Rensi, M | 1 |
| Ferretti, G | 1 |
| Di Gregorio, F | 1 |
| Gómez-de la Fuente, FJ | 1 |
| Martínez-Rodríguez, I | 1 |
| De Arcocha-Torres, M | 1 |
| Quirce, R | 1 |
| Jiménez-Bonilla, J | 1 |
| Martínez-Amador, N | 1 |
| Sánchez-Salmón, A | 1 |
| Lucas-Velázquez, B | 1 |
| Cuenca-Vera, O | 1 |
| Banzo, I | 1 |
| Jehanno, N | 1 |
| Cassou-Mounat, T | 2 |
| Mammar, H | 1 |
| Luporsi, M | 1 |
| Huchet, V | 2 |
| Zattoni, F | 3 |
| Colletti, PM | 5 |
| Rubello, D | 10 |
| Beheshti, M | 1 |
| Haim, S | 1 |
| Zakavi, R | 1 |
| Steinmair, M | 1 |
| Waldenberger, P | 1 |
| Kunit, T | 1 |
| Nader, M | 1 |
| Langsteger, W | 1 |
| Loidl, W | 1 |
| Brogsitter, C | 1 |
| Zöphel, K | 1 |
| Kotzerke, J | 1 |
| Kitajima, K | 2 |
| Murphy, RC | 2 |
| Nathan, MA | 2 |
| Chondrogiannis, S | 4 |
| Marzola, MC | 7 |
| Ferretti, A | 2 |
| Maffione, AM | 3 |
| Rampin, L | 4 |
| Grassetto, G | 4 |
| Afshar-Oromieh, A | 1 |
| Zechmann, CM | 1 |
| Malcher, A | 1 |
| Eder, M | 1 |
| Eisenhut, M | 1 |
| Linhart, HG | 1 |
| Holland-Letz, T | 1 |
| Hadaschik, BA | 1 |
| Giesel, FL | 1 |
| Debus, J | 1 |
| Haberkorn, U | 1 |
| Wetter, A | 2 |
| Lipponer, C | 2 |
| Nensa, F | 2 |
| Heusch, P | 2 |
| Rübben, H | 2 |
| Altenbernd, JC | 1 |
| Schlosser, T | 1 |
| Bockisch, A | 1 |
| Pöppel, T | 1 |
| Lauenstein, T | 1 |
| Nagarajah, J | 2 |
| Ceci, F | 2 |
| Graziani, T | 1 |
| Brunocilla, E | 2 |
| Mazzarotto, R | 1 |
| Ntreta, M | 1 |
| Lodi, F | 2 |
| Martorana, G | 5 |
| Froemming, AT | 1 |
| Hagen, CE | 1 |
| Takahashi, N | 1 |
| Kawashima, A | 1 |
| Freesmeyer, M | 1 |
| Drescher, R | 1 |
| Winkens, T | 1 |
| Schlosser, TW | 1 |
| Pöppel, TD | 1 |
| Lauenstein, TC | 1 |
| Berardi, G | 1 |
| Fodor, A | 1 |
| Busnardo, E | 1 |
| Crivellaro, C | 1 |
| Giovacchini, G | 1 |
| Fiorino, C | 1 |
| Kirienko, M | 1 |
| Incerti, E | 1 |
| Messa, C | 1 |
| Di Muzio, N | 1 |
| Palumbo, B | 1 |
| Sivolella, S | 1 |
| Palumbo, I | 1 |
| Buresta, T | 1 |
| Radicchia, V | 1 |
| Fravolini, ML | 1 |
| Ferretti, F | 1 |
| Bellavita, R | 1 |
| Mearini, L | 1 |
| Scialpi, M | 1 |
| Aristei, C | 1 |
| Pelliccia, G | 1 |
| Veronese, E | 1 |
| Massaro, A | 3 |
| Bolcaen, J | 1 |
| Descamps, B | 1 |
| Deblaere, K | 1 |
| Boterberg, T | 1 |
| De Vos Pharm, F | 1 |
| Kalala, JP | 1 |
| Van den Broecke, C | 1 |
| Decrock, E | 1 |
| Leybaert, L | 1 |
| Vanhove, C | 1 |
| Goethals, I | 1 |
| Garcia, JR | 2 |
| Cuberas, G | 1 |
| Riera, E | 1 |
| Soler, M | 2 |
| Moragas, M | 2 |
| Lomeña, F | 1 |
| Romera, N | 1 |
| Cozar, M | 1 |
| Escobar, M | 1 |
| Colombié, M | 1 |
| Campion, L | 1 |
| Bailly, C | 1 |
| Rusu, D | 1 |
| Rousseau, T | 1 |
| Mathieu, C | 1 |
| Ferrer, L | 1 |
| Rousseau, N | 1 |
| Kraeber-Bodéré, F | 1 |
| Rousseau, C | 1 |
| Minozzi, S | 1 |
| Balduzzi, S | 1 |
| Herrmann, K | 2 |
| Krause, BJ | 2 |
| Oyen, W | 1 |
| Chiti, A | 1 |
| Zanoni, L | 1 |
| Pultrone, C | 1 |
| Malizia, C | 2 |
| Ferrari, M | 1 |
| Rigatti, P | 1 |
| Fonti, C | 1 |
| Pfister, D | 1 |
| Porres, D | 1 |
| Heidenreich, A | 1 |
| Heidegger, I | 1 |
| Knuechel, R | 1 |
| Steib, F | 1 |
| Behrendt, FF | 1 |
| Verburg, FA | 1 |
| Zahr, NM | 1 |
| Carr, RA | 1 |
| Rohlfing, T | 1 |
| Mayer, D | 1 |
| Sullivan, EV | 1 |
| Colrain, IM | 1 |
| Pfefferbaum, A | 1 |
| Balogova, S | 1 |
| Nataf, V | 1 |
| Calzada, M | 1 |
| Kerrou, K | 1 |
| Devaux, JY | 1 |
| Mohty, M | 1 |
| Talbot, JN | 1 |
| Garderet, L | 1 |
| von Eyben, FE | 1 |
| Kairemo, K | 1 |
| Mandoliti, G | 1 |
| Pasini, F | 1 |
| Steiner, Ch | 1 |
| Vees, H | 1 |
| Zaidi, H | 1 |
| Wissmeyer, M | 1 |
| Berrebi, O | 1 |
| Kossovsky, MP | 1 |
| Khan, HG | 1 |
| Miralbell, R | 2 |
| Ratib, O | 1 |
| Buchegger, F | 1 |
| Milne, A | 1 |
| MacQueen, GM | 1 |
| Yucel, K | 1 |
| Soreni, N | 1 |
| Hall, GB | 1 |
| Jadvar, H | 1 |
| Ito, K | 2 |
| Yokoyama, J | 2 |
| Kubota, K | 2 |
| Morooka, M | 2 |
| Shiibashi, M | 1 |
| Matsuda, H | 1 |
| Fuccio, C | 4 |
| Santi, I | 1 |
| Allegri, V | 1 |
| Montini, GC | 1 |
| Ambrosini, V | 2 |
| Boschi, S | 2 |
| Wu, HB | 1 |
| Wang, QS | 1 |
| Wang, MF | 1 |
| Li, HS | 1 |
| Al-Nahhas, A | 2 |
| Würschmidt, F | 1 |
| Petersen, C | 1 |
| Wahl, A | 1 |
| Dahle, J | 1 |
| Kretschmer, M | 1 |
| Celli, M | 1 |
| Profitos, MB | 1 |
| Pettinato, V | 1 |
| Graute, V | 1 |
| Jansen, N | 1 |
| Ubleis, C | 1 |
| Seitz, M | 1 |
| Hartenbach, M | 1 |
| Scherr, MK | 1 |
| Thieme, S | 1 |
| Cumming, P | 1 |
| Klanke, K | 1 |
| Tiling, R | 1 |
| Bartenstein, P | 1 |
| Hacker, M | 1 |
| Soyka, JD | 1 |
| Muster, MA | 1 |
| Schmid, DT | 1 |
| Seifert, B | 1 |
| Schick, U | 1 |
| Jorcano, S | 1 |
| Zaugg, K | 1 |
| Seifert, HH | 1 |
| Veit-Haibach, P | 1 |
| Strobel, K | 1 |
| Schaefer, NG | 1 |
| Husarik, DB | 1 |
| Hany, TF | 1 |
| Kwee, SA | 1 |
| Coel, MN | 1 |
| Lim, J | 1 |
| Gu, CN | 1 |
| Hunt, CH | 1 |
| Lehman, VT | 1 |
| Johnson, GB | 1 |
| Diehn, FE | 1 |
| Schwartz, KM | 1 |
| Eckel, LJ | 1 |
| Mamede, M | 1 |
| Marcolongo, A | 1 |
| Inglese, M | 1 |
| Li, BS | 1 |
| Rusinek, H | 1 |
| Babb, JS | 1 |
| Grossman, RI | 1 |
| Gonen, O | 1 |
| Obergriesser, T | 1 |
| Ende, G | 1 |
| Braus, DF | 1 |
| Henn, FA | 1 |
| Sassi, RB | 1 |
| Stanley, JA | 1 |
| Axelson, D | 1 |
| Brambilla, P | 1 |
| Nicoletti, MA | 1 |
| Keshavan, MS | 1 |
| Ramos, RT | 1 |
| Ryan, N | 1 |
| Birmaher, B | 1 |
| Soares, JC | 1 |
| Cimitan, M | 1 |
| Bortolus, R | 1 |
| Morassut, S | 1 |
| Canzonieri, V | 1 |
| Garbeglio, A | 1 |
| Baresic, T | 1 |
| Borsatti, E | 1 |
| Drigo, A | 1 |
| Trovò, MG | 1 |
| Souvatzoglou, M | 1 |
| Tuncel, M | 1 |
| Buck, AK | 1 |
| Praus, C | 1 |
| Schuster, T | 1 |
| Geinitz, H | 1 |
| Treiber, U | 1 |
| Schwaiger, M | 1 |
| Bizzi, A | 1 |
| Movsas, B | 1 |
| Tedeschi, G | 1 |
| Phillips, CL | 1 |
| Okunieff, P | 1 |
| Alger, JR | 1 |
| Di Chiro, G | 1 |
| Tsimmerman, IaS | 2 |
| Kiseleva, RP | 1 |
| Freĭnd, GG | 1 |
| Pan, JW | 1 |
| Hetherington, HP | 1 |
| Vaughan, JT | 1 |
| Mitchell, G | 1 |
| Pohost, GM | 1 |
| Whitaker, JN | 1 |
| Sarchielli, P | 1 |
| Presciutti, O | 1 |
| Tarducci, R | 1 |
| Gobbi, G | 1 |
| Alberti, A | 1 |
| Pelliccioli, GP | 1 |
| Orlacchio, A | 1 |
| Gallai, V | 1 |
| Rabinovich, IM | 1 |
| Banchenko, GV | 1 |
| Rabinovich, OF | 1 |
| Klijn, CJ | 1 |
| Kappelle, LJ | 1 |
| van der Grond, J | 1 |
| Algra, A | 1 |
| Tulleken, CA | 1 |
| van Gijn, J | 1 |
| Floeth, FW | 1 |
| Wittsack, HJ | 1 |
| Engelbrecht, V | 1 |
| Weber, F | 1 |
| Syman, LN | 1 |
| Golovanova, ES | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China[NCT01840072] | 4,071 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients With Biochemical Recurrence of Prostate Cancer After Previous Treatment With Curative Intent[NCT05622162] | Phase 3 | 106 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting | ||
| [NCT02964351] | 120 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) PET/CT Utilizing the High Resolution Digital Philips Vereos Scanner, in Patients With Biochemical Recurrence After Radical Prostatectomy[NCT04234399] | 22 participants (Actual) | Observational | 2020-03-01 | Active, not recruiting | |||
| A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer[NCT05936658] | Phase 3 | 89 participants (Anticipated) | Interventional | 2023-05-08 | Recruiting | ||
| F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide[NCT01981707] | Phase 2/Phase 3 | 12 participants (Actual) | Interventional | 2013-12-31 | Terminated (stopped due to enrollment default) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death (NCT01840072)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 502 |
| Active Antihypertensive Treatment | 500 |
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. (NCT01840072)
Timeframe: 2 weeks
| Intervention | participants (Number) |
|---|---|
| Usual Care | 681 |
| Active Antihypertensive Treatment | 683 |
Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education <12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of <26. (NCT01840072)
Timeframe: Three months
| Intervention | MoCA score (Median) |
|---|---|
| Usual Care | 22 |
| Active Antihypertensive Treatment | 22 |
Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment). (NCT01840072)
Timeframe: Three months
| Intervention | MMSE score (Median) |
|---|---|
| Usual Care | 26 |
| Active Antihypertensive Treatment | 26 |
Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale. (NCT01840072)
Timeframe: Three months
| Intervention | Score on modified Rankin scale (Median) |
|---|---|
| Usual Care | 1.0 |
| Active Antihypertensive Treatment | 1.0 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Active Antihypertensive Treatment | 68 |
| Usual Care | 54 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Usual Care | 59 |
| Active Antihypertensive Treatment | 48 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Active Antihypertensive Treatment | 28 |
| Usual Care | 43 |
10 reviews available for choline and Recrudescence
| Article | Year |
|---|---|
PSMA PET imaging in the diagnosis and management of prostate cancer.
Topics: Choline; Humans; Male; Molecular Targeted Therapy; Neoplasm Staging; Positron Emission Tomography Co | 2023 |
Topics: Choline; Humans; Hyperparathyroidism; Magnetic Resonance Imaging; Positron Emission Tomography Compu | 2020 |
Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Androgens; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Positron | 2013 |
18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.
Topics: Acetates; Carbon; Choline; Humans; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tom | 2013 |
11C-choline PET/CT and PSA kinetics.
Topics: Carbon Radioisotopes; Choline; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Prost | 2013 |
Choline PET/CT for imaging prostate cancer: an update.
Topics: Choline; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Prostatic Neoplasms; Recurr | 2013 |
New acquisition protocol of 18F-choline PET/CT in prostate cancer patients: review of the literature about methodology and proposal of standardization.
Topics: Adult; Aged; Aged, 80 and over; Choline; Humans; Lymph Nodes; Male; Middle Aged; Positron-Emission T | 2014 |
PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.
Topics: Carbon Radioisotopes; Choline; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms; Recu | 2016 |
Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
Topics: Carbon Radioisotopes; Choline; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; | 2016 |
Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer.
Topics: Choline; Humans; Kinetics; Male; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic | 2011 |
10 trials available for choline and Recrudescence
| Article | Year |
|---|---|
Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Niacinamide; Oligopeptides; Positron Em | 2019 |
Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Choline; Humans; Male; Middle Aged; Positron Emission Tomog | 2017 |
Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Topics: Aged; Androgens; Choline; Humans; Kinetics; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emi | 2013 |
Dual-phase 11C-choline PET/computed tomography in the early evaluation of prostate cancer recurrence.
Topics: Aged; Carbon Radioisotopes; Choline; Feasibility Studies; Half-Life; Humans; Male; Multimodal Imagin | 2015 |
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carbon Radioisotopes; Carboxylic Acids; Choline; Cyclobutan | 2016 |
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carbon Radioisotopes; Carboxylic Acids; Choline; Cyclobutan | 2016 |
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carbon Radioisotopes; Carboxylic Acids; Choline; Cyclobutan | 2016 |
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carbon Radioisotopes; Carboxylic Acids; Choline; Cyclobutan | 2016 |
18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence.
Topics: Aged; Carbon Radioisotopes; Choline; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Foll | 2010 |
[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.
Topics: Aged; Carcinoma; Choline; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Sta | 2011 |
Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging.
Topics: Aged; Aged, 80 and over; Choline; Disease Progression; Humans; Male; Middle Aged; Multimodal Imaging | 2012 |
Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis.
Topics: Adult; Aspartic Acid; Brain; Choline; Corpus Callosum; Creatine; Diffusion; Female; Humans; Magnetic | 2003 |
[A clinical study of Solcoseryl Dental Adhesive Paste and Mundisal gel in the treatment of chronic recurrent aphthous and herpetic stomatitides].
Topics: Actihaemyl; Adult; Anti-Inflammatory Agents, Non-Steroidal; Choline; Chronic Disease; Drug Combinati | 1999 |
57 other studies available for choline and Recrudescence
| Article | Year |
|---|---|
[Intermediate-risk prostate cancer treated with exclusive external irradiation: Focus on anatomical sites of recurrence in two French trials].
Topics: Choline; Humans; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; | 2022 |
Choline elevation in amygdala region at recovery indicates longer survival without depressive episode: a magnetic resonance spectroscopy study.
Topics: Adult; Amygdala; Antidepressive Agents; Aspartic Acid; Brain; Choline; Depression; Humans; Magnetic | 2021 |
18F-choline positron emission tomography/computed tomography for the detection of prostate cancer relapse: assessment of maximum standardized uptake value correlation with prostate-specific antigen levels.
Topics: Aged; Biological Transport; Choline; Humans; Male; Positron Emission Tomography Computed Tomography; | 2019 |
Nodular Fat-Sparing Hepatic Parenchyma as 11C-Choline-Avid Finding on PET/CT.
Topics: Adipose Tissue; Aged; Carbon Radioisotopes; Choline; Diagnosis, Differential; Humans; Liver; Male; M | 2020 |
Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Choline; Contrast Media; Disease-Free Sur | 2020 |
Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20 ng/mL.
Topics: Aged; Carbon Radioisotopes; Choline; False Negative Reactions; Humans; Male; Middle Aged; Neoplasm S | 2020 |
Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke.
Topics: Aged; Betaine; Cardiovascular Diseases; Case-Control Studies; Choline; Female; Humans; Lipotropic Ag | 2021 |
18F-Fluorocholine, 18F-FDG, and 18F-Fluoroethyl Tyrosine PET/CT in Parathyroid Cancer.
Topics: Aged; Choline; Female; Fluorodeoxyglucose F18; Humans; Parathyroid Neoplasms; Positron Emission Tomo | 2017 |
18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
Topics: Aged; Choline; Contrast Media; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Stagi | 2017 |
Incidental Papillary Bladder Carcinoma on 18F-Fluoromethylcholine PET/CT Undertaken to Evaluate Prostate Malignancy.
Topics: Aged; Carcinoma, Papillary; Choline; Humans; Incidental Findings; Male; Positron Emission Tomography | 2017 |
Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Topics: Aged; Androgens; Choline; Humans; Male; Neoplasm Metastasis; Positron Emission Tomography Computed T | 2018 |
Salvage extended field or involved field nodal irradiation in
Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Positron Emission Tomography Computed T | 2019 |
Choline and N-acetyl aspartate levels in the dorsolateral prefrontal cortex at the beginning of the recovery phase as markers of increased risk for depressive episode recurrence under different duration of maintenance therapy and after it: a retrospective
Topics: Adolescent; Adult; Antidepressive Agents; Aspartic Acid; Biomarkers; Choline; Depressive Disorder; F | 2018 |
Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.
Topics: Aged; Choline; Humans; Male; Mesothelioma; Pleural Neoplasms; Positron Emission Tomography Computed | 2019 |
Effect of positive carbon-11-choline PET/CT results in the therapeutic management of prostate cancer biochemical relapse.
Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Humans; Male; Middle Aged; Positron Emission | 2019 |
18F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence.
Topics: Brain Neoplasms; Choline; Hemangiopericytoma; Humans; Male; Middle Aged; Neoplasm, Residual; Positro | 2019 |
Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.
Topics: Aged; Aged, 80 and over; Brachytherapy; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Posi | 2013 |
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Choline; Gallium Radioisotopes; Glutamate Carboxypeptida | 2014 |
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Choline; Gallium Radioisotopes; Glutamate Carboxypeptida | 2014 |
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Choline; Gallium Radioisotopes; Glutamate Carboxypeptida | 2014 |
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Choline; Gallium Radioisotopes; Glutamate Carboxypeptida | 2014 |
Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Choline; Humans; Lymphatic Metastasis; Magnetic Resonance I | 2014 |
11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Humans; Male; Middle Aged; Multimodal Imagin | 2014 |
Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carbon Radioisotopes; Choline; Humans; Image Processing, | 2014 |
Unexpected diagnosis of peripheral schwannoma on 18F-fluoroethylcholine PET/CT for localization of prostate cancer recurrence and biopsy under real-time PET/ultrasound fusion guidance.
Topics: Aged; Choline; Humans; Image Processing, Computer-Assisted; Image-Guided Biopsy; Incidental Findings | 2014 |
Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis.
Topics: Aged; Aged, 80 and over; Biological Transport; Bone Neoplasms; Carbon Radioisotopes; Choline; Diffus | 2014 |
(11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.
Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Feasibility Studies; Humans; Lymphatic Metas | 2014 |
Influence of hormonal therapy in prostate cancer patients undergoing [18F]fluoromethyl choline PET/CT: a retrospective study.
Topics: Aged; Aged, 80 and over; Biological Transport; Choline; Hormones; Humans; Male; Middle Aged; Positro | 2016 |
(18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Choline; Diagnosis, Differential; Female; Fluorodeoxyglu | 2015 |
(11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Carbon Radioisotopes; Choline; Combined Modality Therapy; Humans; Ly | 2015 |
Optimized protocol for (18)F-choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases.
Topics: Aged; Choline; Fluorine Radioisotopes; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emiss | 2015 |
Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
Topics: Aged; Aged, 80 and over; Choline; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Age | 2015 |
Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.
Topics: Aged; Choline; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Lymph Node Excision; Ma | 2016 |
Brain metabolite levels in recently sober individuals with alcohol use disorder: Relation to drinking variables and relapse.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain; Choline; Chronic Dise | 2016 |
Can (68)GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?
Topics: Aged; Choline; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Isotope Labeling; Lymph | 2016 |
18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
Topics: Aged; Aged, 80 and over; Choline; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Male; | 2016 |
Pituitary Non-Functioning Adenoma Disclosed at 18F-Choline PET/CT to Investigate a Prostate Cancer Relapse.
Topics: Adenoma; Choline; Humans; Incidental Findings; Male; Middle Aged; Pituitary Neoplasms; Positron Emis | 2016 |
Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.
Topics: Aged; Aged, 80 and over; Choline; Fluorine Radioisotopes; Humans; Male; Middle Aged; Neoplasm Recurr | 2009 |
Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study.
Topics: Adult; Analysis of Variance; Aspartic Acid; Choline; Depressive Disorder, Major; Female; Glutamic Ac | 2009 |
Influence of trigger PSA and PSA kinetics on (11)C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Topics: Carbon Radioisotopes; Choline; Humans; Kinetics; Male; Positron-Emission Tomography; Prostate-Specif | 2010 |
Comparison of 18F-FDG and 11C-choline PET/CT for detecting recurrences in patients with nonsquamous cell head and neck malignancies.
Topics: Biological Transport; Carbon Radioisotopes; Choline; Female; Fluorodeoxyglucose F18; Head and Neck N | 2010 |
Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Carbon Radioisotopes; Choline; Early Detection of Can | 2011 |
Utility of ¹¹C-choline imaging as a supplement to F-18 FDG PET imaging for detection of thyroid carcinoma.
Topics: Adult; Aged; Carbon Radioisotopes; Choline; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Age | 2011 |
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Biological Transport; Carbon Rad | 2011 |
Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.
Topics: Aged; Aged, 80 and over; Choline; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kinetics; Lymph | 2012 |
Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer.
Topics: Adult; Aged; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; P | 2012 |
Benign fibrous dysplasia on [(11)C]choline PET: a potential mimicker of disease in patients with biochemical recurrence of prostate cancer.
Topics: Aged; Carbon Radioisotopes; Choline; Diagnosis, Differential; Fibrous Dysplasia of Bone; Humans; Mal | 2012 |
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
Topics: Aged; Aged, 80 and over; Biopsy; Carbon Isotopes; Choline; Hormones; Humans; Image Processing, Compu | 2013 |
Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analys | 2013 |
Long-term follow-up of magnetic resonance-detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy.
Topics: Aspartic Acid; Choline; Cognition Disorders; Creatine; Depressive Disorder, Major; Electroconvulsive | 2003 |
Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients.
Topics: Adolescent; Adult; Age Factors; Aspartic Acid; Bipolar Disorder; Child; Choline; Creatine; Female; H | 2005 |
[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.
Topics: Aged; Aged, 80 and over; Cell Differentiation; Cell Proliferation; Choline; Humans; Male; Middle Age | 2006 |
The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Carbon Radioisotopes; Choline; Humans; Male; Middle A | 2008 |
Response of non-Hodgkin lymphoma to radiation therapy: early and long-term assessment with H-1 MR spectroscopic imaging.
Topics: Aspartic Acid; Brain Neoplasms; Choline; Creatine; Female; Follow-Up Studies; Humans; Lipid Metaboli | 1995 |
[The validation and effect of the prophylactic (antirelapse) treatment of peptic ulcer patients with chlorozil and metronidazole].
Topics: Adult; Anti-Ulcer Agents; Choline; Drug Evaluation; Duodenal Ulcer; Female; Follow-Up Studies; Human | 1996 |
Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T.
Topics: Adult; Aspartic Acid; Astrocytes; Axons; Brain; Cell Membrane; Cerebral Ventricles; Choline; Creatin | 1996 |
1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study.
Topics: Adult; Brain; Choline; Creatinine; Disability Evaluation; Humans; Inositol; Interferon-beta; Magneti | 1998 |
Magnetic resonance techniques for the identification of patients with symptomatic carotid artery occlusion at high risk of cerebral ischemic events.
Topics: Adult; Aged; Aspartic Acid; Brain Ischemia; Carotid Arteries; Carotid Stenosis; Choline; Comorbidity | 2000 |
Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastoma--Report of two exceptional cases.
Topics: Adult; Brain Neoplasms; Choline; Fatal Outcome; Female; Glioblastoma; Humans; Image Processing, Comp | 2002 |
[Experience with objective evaluation of the action of cimetidine--a blocker of histamine-H2 receptors--in patients with peptic ulcer of the duodenum].
Topics: Anti-Ulcer Agents; Atropine; Choline; Cimetidine; Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Gast | 1986 |